Research & Development

Clinical Trials

Intralytix is dedicated to advancing human health through rigorous clinical research. Explore our ongoing and completed FDA-approved clinical trials below.

EcoActive™

Targeting adherent-invasive E. coli (AIEC) in Crohn's disease

Baltimore Metro Area, MD

Trial Details

New York, NY

Trial Details

ShigActive™

Targeting Shigella, the causative agent of dysentery

Baltimore, MD

Trial Details

VRELysin™

Targeting vancomycin-resistant Enterococci in the gut

Pittsburgh, PA

Trial Details

Expanded Access

Intralytix offers expanded access programs for patients with serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives.